![Shannon Rourke Devens](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shannon Rourke Devens
Corporate Officer/Principal presso SURFACE ONCOLOGY, INC.
Profilo
Shannon Rourke Devens is currently working as the Senior Vice President-Development Operation at Surface Oncology, Inc. Prior to this, Shannon worked as the Senior Director-Clinical Operations at Infinity Pharmaceuticals, Inc. Shannon holds a graduate degree from Northeastern University and an undergraduate degree from the University of Colorado Boulder.
Posizioni attive di Shannon Rourke Devens
Società | Posizione | Inizio |
---|---|---|
SURFACE ONCOLOGY, INC. | Corporate Officer/Principal | 15/12/2021 |
Precedenti posizioni note di Shannon Rourke Devens
Società | Posizione | Fine |
---|---|---|
INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formazione di Shannon Rourke Devens
Northeastern University | Graduate Degree |
University of Colorado Boulder | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
INFINITY PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 1 |
---|---|
Surface Oncology, Inc.
![]() Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Shannon Rourke Devens